Hormone Receptor-positive Breast Cancer Clinical Trials

65 clinical trials for Hormone Receptor-positive Breast Cancer across international registries, including 28 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC — RECRUITING · PHASE2
• An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer — RECRUITING · PHASE3
• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors — RECRUITING · PHASE1
• Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer — RECRUITING · PHASE2
• Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure — RECRUITING · PHASE1
• ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer — RECRUITING · PHASE2
• CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment — RECRUITING · PHASE2
• BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer — RECRUITING · PHASE1
• Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer — RECRUITING · PHASE1
• Study of XB010 in Subjects With Solid Tumors — RECRUITING · PHASE1
• PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) — RECRUITING · PHASE2
• EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC) — RECRUITING
• ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer — RECRUITING · PHASE2
• DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients — RECRUITING
• A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer — RECRUITING · PHASE1
• Study of Screening Brain MRIs in Stage IV Breast Cancer — RECRUITING · PHASE2
• ETHAN - ET for Male BC — RECRUITING · PHASE2
• VS-6766+Abema+Fulv in Met HR+/HER- BC — RECRUITING · PHASE1
• Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea — RECRUITING
• Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer — RECRUITING · PHASE2
• A Study of Revaree Plus in People With Breast Cancer — RECRUITING · PHASE4
• Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer — RECRUITING · PHASE2
• Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd — RECRUITING
• PRE-I-SPY Phase I/Ib Oncology Platform Program — RECRUITING · PHASE1
• Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer — RECRUITING · PHASE2
• Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study — RECRUITING
• Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients — RECRUITING · PHASE4
• A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC — RECRUITING · PHASE2
• Telehealth Intervention for Symptom Management and Adherence to Adjuvant Endocrine Therapy — NOT_YET_RECRUITING · NA
• Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer — NOT_YET_RECRUITING · PHASE2
• Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial — NOT_YET_RECRUITING · PHASE2
• Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer — COMPLETED · PHASE1
• A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors — COMPLETED · PHASE1
• ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer — COMPLETED · PHASE1
• A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer — TERMINATED · PHASE1
• An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04) — TERMINATED · PHASE3
• A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positive Breast Cancer — NOT_YET_RECRUITING · NA
• A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. — COMPLETED · PHASE3
• Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• RWE About QOL and Compliance of Patients With OFS in China — COMPLETED
• Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) — ACTIVE_NOT_RECRUITING · PHASE1
• TH1902 in Patients With Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Study of XB002 in Subjects With Solid Tumors (JEWEL-101) — COMPLETED · PHASE1
• WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor — COMPLETED · PHASE1
• Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer — OTHER · PHASE2
• Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial — ACTIVE_NOT_RECRUITING · PHASE2
• A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer — COMPLETED · PHASE2

Refine this search